✦ LIBER ✦

Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin

✍ Scribed by C. Roux; C. Pelissier; V. Listrat; S. Kolta; C. Simonetta; M. Guignard; M. Dougados; B. Amor

Publisher: Springer-Verlag
Year: 1995
Tongue: English
Weight: 687 KB
Volume: 5
Category: Article
ISSN: 0937-941X
DOI: 10.1007/bf02106098

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Changes in bone mineral density and body

Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma

✍ Hang Lee; Katelyn McGovern; Joel S. Finkelstein; Matthew R. Smith 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

## Abstract ## BACKGROUND Initial treatment with a gonadotropin‐releasing hormone (GnRH) agonist increases fat mass, decreases lean body mass, and decreases bone mineral density (BMD) in men with prostate carcinoma. To the authors' knowledge, little is known regarding either the long‐term effects

Increasing use of gonadotropin-releasing

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

✍ Vahakn B. Shahinian; Yong-fang Kuo; Jean L. Freeman; Eduardo Orihuela; James S. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB 👁 1 views

Slipped capital femoral epiphysis during

Slipped capital femoral epiphysis during the treatment of precocious puberty with a gonadotropin-releasing hormone-agonist: aetiological considerations

✍ Fumiko Yamato; Junji Takaya; Hirohiko Higashino; Yasuo Yamanouchi; Hiroshi Sueha 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 170 KB

Basal serum pituitary hormone levels and

Basal serum pituitary hormone levels and outcome of in vitro fertilization utilizing a flare nasal gonadotropin releasing hormone agonist and fixed low-dose follicle-stimulating hormone/human menopausal gonadotropin regimen

✍ Y. F. Chan; P. C. Ho; W. W. K. So; W. S. B. Yeung 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 338 KB

Bone fractures associated with luteinizi

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

✍ Murphy F. Townsend; W. Holt Sanders; Robert O. Northway; Sam D. Graham Jr. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 2 views

## Background: Luteinizing hormone-releasing hormone agonists (lhrh-a) have become an established treatment for certain patients with prostate carcinoma. lhrh-a are known to decrease bone mineral density. the purpose of this study was to determine the risk of bone fracture in men receiving lhrh-a f

The use of long-acting gonadotropin-rele

The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; decapeptyl) and gonadotropins versus short-acting GnRH-a (Buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF)

✍ Yael Gonen; Martha Dirnfeld; Shlomit Goldman; Mara Koifman; Haim Abramovici 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 531 KB